Krystal Biotech (KRYS) just unveiled an announcement.
Krystal Biotech, Inc. showcased their innovative research through a poster at the ARVO 2024 Annual Meeting, revealing a novel HSV-1-Based Vector Platform for targeted drug delivery to the posterior of the eye. This advancement, which could be a game-changer for ophthalmic treatments, is accessible for public viewing on the company’s website, highlighting their commitment to transparency and investor engagement in their scientific progress.
For detailed information about KRYS stock, go to TipRanks’ Stock Analysis page.
